Download Now Free registration required
Neither the Japanese Government nor its physicians, pharmacies and patients are hostile to foreign drugs and Active Pharmaceutical Ingredients (APIs) in principle. In practice, however, there is significant resistance to foreign generics. Japan has long been the target of foreign innovators, who therefore undoubtedly have better knowledge of the local market than those foreign generic companies that have not previously entered the country, and hence may be better placed to succeed in the generic space. AstraZeneca, Abbott, Pfizer, Roche, Merck, Novartis and Boehringer Ingelheim are all building up a presence in the country.
- Format: PDF
- Size: 1677.8 KB